ReviewGerman medical science : GMS e-journal2015
Use of a German longitudinal prescription database (LRx) in pharmacoepidemiology.
Review in German medical science : GMS e-journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Between Guidelines and Daily Practice: The Persistent Use of Parenteral Depot Corticosteroids in Germany.Clinical and translational allergy · 2026Article
- The COVID-19 pandemic and the use of benzodiazepines and benzodiazepine-related drugs in Estonia: an interrupted time-series analysis.Child and adolescent psychiatry and mental health · 2024Article
- Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx).Cardiology and therapy · 2024Article
- Real-world characteristics and use patterns of patients treated with vericiguat: A nationwide longitudinal cohort study in Germany.European journal of clinical pharmacology · 2024Article
- Treatment persistence and switching patterns of ABP 501 in European patients with inflammatory bowel disease.Therapeutic advances in gastroenterology · 2024Article
- Epidemiology and treatment of children with hereditary angioedema in Germany: A retrospective database study.Clinical and translational allergy · 2023Article
- Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study.Advances in therapy · 2023Article
- Persistence with tamoxifen and aromatase inhibitors in Germany: a retrospective cohort study with 284,383 patients.Journal of cancer research and clinical oncology · 2023Article
- Article
- The Treatment Patterns with Brolucizumab in Germany (REALIZE) Study: A Retrospective Cohort Study Based on Longitudinal Prescription Data.Ophthalmology and therapy · 2023Article
- Machine Learning Can Predict the Probability of Biologic Therapy in Patients with Inflammatory Bowel Disease.Journal of clinical medicine · 2022Article
- Article
- Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real-World Study Across Antipsychotics.Clinical and translational science · 2020Article
- Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany .International journal of clinical pharmacology and therapeutics · 2020Observational
- Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany.European journal of heart failure · 2019Article
- Article
- Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany.Diabetes, metabolic syndrome and obesity : targets and therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Large epidemiological databases are often used to examine matters pertaining to drug utilization, health services, and drug safety. The major strength of such databases is that they include large sample sizes, which allow precise estimates to be made. The IMS® LRx database has in recent years been used as a data source for epidemiological research. The aim of this paper is to review a number of recent studies published with the aid of this database and compare these with the results of similar studies using independent data published in the literature. In spite of being somewhat limited to studies for which comparative independent results were available, it was possible to include a wide range of possible uses of the LRx database in a variety of therapeutic fields: prevalence/incidence rate determination (diabetes, epilepsy), persistence analyses (diabetes, osteoporosis), use of comedication (diabetes), drug utilization (G-CSF market) and treatment costs (diabetes, G-CSF market). In general, the results of the LRx studies were found to be clearly in line with previously published reports. In some cases, noticeable discrepancies between the LRx results and the literature data were found (e.g. prevalence in epilepsy, persistence in osteoporosis) and these were discussed and possible reasons presented. Overall, it was concluded that the IMS® LRx database forms a suitable database for pharmacoepidemiological studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.